We report the cloning and characterization of a cDNA encoding a second human cyclosporin A-binding protein (hCyPB). Homology analyses reveal that hCyPB is a member of the cyclophilin B (CyPB) family, which includes yeast CyPB, Drosophila nina A, and rat cyclophilin-like protein. This family is distinguished from the cyclophilin A (CyPA) family by the presence of endoplasmic reticulum (ER)-directed signal sequences. hCyPB has a hydrophobic leader sequence not found in hCyPA, and its first 25 amino acids are removed upon expression in Escherichia coli. Moreover, we show that hCyPB is a peptidyl-prolyl cis-trans isomerase which can be inhibited by cyclosporin A. These observations suggest that other members of the CyPB family will have similar enzymatic properties. Sequence comparisons of the CyPB proteins show a central, 165-amino acid peptidyl-prolyl isomerase and cyclosporin A-binding domain, flanked by variable N-terminal and C-terminal domains. These two variable regions may impart compartmental specificity and regulation to this family of cyclophilin proteins containing the conserved core domain. Northern blot analyses show that hCyPB mRNA is expressed in the Jurkat T-cell line, consistent with its possible target role in cyclosporin A-mediated immunosuppression.
The cyclophilins (CyPs) are a conserved class of proteins that bind the immunosuppressive drug cyclosporin A (CsA) with high affinity (Kd = 5-200 nM) (1, 2) . CsA blocks helper T-cell activation at a step between T-cell receptor stimulation and the transcriptional activation of cytokine genes (encoding interleukin 2, interleukin 3, granulocyte-macrophage colonystimulating factor, y-interferon) (3, 4) . Because the affinities of CsA derivatives for CyP correlate with their immunosuppressive activities, CyP has been implicated in the helper T-cell signal transduction pathway (2, 5) . CyPs from many species possess peptidyl-prolyl cis-trans isomerase (PPIase) activity which is blocked by CsA and therefore may be relevant in CsA-mediated immunosuppression (6, 7) .
Definitive support for the idea that CyP plays a critical role in T-cell signal transduction has not been presented. Surprisingly, CyPs are found in all cell types examined, at high concentrations not likely to be saturated by therapeutic levels of CsA (1, 2, 8) . Moreover, CsA affinity columns bind an array of proteins in addition to the major CyP species (2, 9) . Therefore, the formal possibility exists that the therapeutically relevant target is a less abundant protein with a higher affinity for CsA. To elucidate the mechanism by which CsA interferes with T-cell activation and to understand the role of CyPs in the cell, intense efforts have focused on the interactions of CsA with human CyP and its homologues in mammalian, fungal, and prokaryotic species. To expand this effort to other potential cellular targets of CsA, human cDNA libraries were probed with the only known human CyP cDNA under reduced stringencies, and a second CyP gene, encoding human CyP B (hCyPB), was discovered.A The protein is 64% identical to human CyP A (hCyPA) and is distinguished from it by a signal sequence that probably directs it to the endoplasmic reticulum (ER) . hCyPB has even stronger similarity to yeast CyPB (yCyPB) (10) , which also has an ER-directed signal sequence. The signal sequence is removed from hCyPB upon expression in Escherichia coli, and the processed protein possesses PPIase activity that is inhibited by CsA.
MATERIALS AND METHODS
Materials. The polymerase chain reaction (PCR) kit and Thermus aquaticus (Taq) DNA polymerase were purchased from Perkin-Elmer/Cetus. Sequenase was purchased from United States Biochemical. The tetrapeptide substrate N-succinyl-Ala-Ala-Pro-Phe p-nitroanilide, a-chymotrypsin, and biochemicals used in the enzyme purification were purchased from Sigma. The Jurkat cDNA library was obtained from Clontech. The endothelial cDNA was kindly provided by D. Littman (University of California, San Francisco). CsA was a generous gift from Sandoz. Nylon membranes (Biotrans) used in the Northern blot analyses were obtained from ICN.
Enzyme assays were performed on a Hewlett-Packard 8452 diode array spectrophotometer, and the first-order rate constants were derived as previously described (11) . The Northern blot analyses were quantitated by using a Betascope detector (Betagen, Waltham, MA).
The PCR primers used to amplify the human CyPB gene for overexpression are as follows. For the N-terminal primer (LZ#33), the Shine-Dalgarno sequences are underlined, and the ATG start codons are in boldface. The corresponding C-terminal primer (LZ#34) has the complementary sequence to the hCyPB gene in boldface. Primer LZ#33, 5'-GT CGA CGA ATT CCT GCA GAA GA GAT ATA CAT ATG AAG GTG CTC CTT GCC GCC GCC-3'; LZ#34 5'-GAG CTC CTA GGA TCC AAG CTT CTA CTC CTT GGC GAT GGC the lithium chloride method (14) . The RNA (20 jig) was
Construction of an Overexpression Vector for hCyPB. The fractionated on a 1% agarose gel containing 20 mM 3-(NhCyPB coding sequence was amplified by PCR using the ,ug/ml) was grown to an OD6w of 0.6, induced with 1 mM isopropyl 8-D-thiogalactopyranoside, and harvested 9 hr later, yielding approximately 5 g/liter of cells (wet weight). The cells were lysed by two passes through a French press at 16,000 psi (110 MPa). After centrifugation (20 ,000 x g, 25 min), the protein was purified (11), yielding 1 mg of a 21-kDa protein of greater than 90% purity.
Protein Characterizations. The protein concentrations were determined by Bradford assays (17) , and the proteins were analyzed on denaturing SDS/15% polyacrylamide gels.
CyP activity assay. The enzyme assay employed was a modification of an assay using the tetrapeptide substrate N-succinyl-Ala-Ala-Pro-Phe p-nitroanilide (AAPF) (18, 19) . The assay was performed at 10°C, in 35 mM Hepes buffer (pH 8.0), 100 ,uM AAPF [dissolved in 66% (vol/vol) dimethyl sulfoxide], and a-chymotrypsin at 250 ,g/ml, while CyP concentration was varied (3.45-58 nM). The reaction mixture was incubated at 10°C, and the reaction was initiated by the addition of a-chymotrypsin. An absorbance reading at 390 nm was taken every 0.5 sec. Domains I II ICso determination. The enzyme assay described above was performed with the addition of various final concentrations of CsA (dissolved in ethanol) in the range of0-1000 nM.
RESULTS
Isolation and Sequencing an hCyPB cDNA. To search for related human CyP cDNAs, the hCyPA cDNA (11) was used to screen human endothelial and Jurkat T-cell cDNA libraries. As described in Materials and Methods, several candidate clones yielding lower hybridization signals than hCyPA were analyzed by restriction mapping. All five yielded identical maps which were distinct from the hCyPA map. The DNA and deduced amino acid sequence of the longest cDNA are presented in Fig. 1 Upper. This cDNA has an open reading frame encoding 208 amino acids and shows a high degree of identity with yCyPB ( Fig. 1 Lower) . Therefore, this protein will be referred to as hCyPB.
A sequence alignment and comparison of hCyPB with hCyPA, yCyPB, and rCyLP (20) revealed a set of domains which have various degrees of conservation. These domains are schematically presented in Fig. 2 , and they have been labeled domains I through VI. From Figs. 1 Upper and 2, it is clear that hCyPB is more structurally similar to yCyPB and rCyLP than it is to hCyPA. The 33-amino acid domain I in hCyPB, yCyPB, and rCyLP contains characteristic ERdirected signal sequences (21, 22) and is absent from hCyPA. Domain II has 61 amino acids and at least 46% identity between the two families of CyPs. Domain III has 77 amino acids and represents the most conserved region of the larger core domain and contains the conserved tryptophan thought to interact with CsA (refs. 23 and 24; J. Liu, C.-M. Chen, and C. T. Walsh, unpublished results). Domain II and domain III of hCyPB have maintained a higher degree of conservation to hCyPA than they have to nina A and yeast CyPB, both nominally CyPB proteins. Domain IV, which has 27 amino acids, is the least conserved region of the core domain shared by both families of CyPs. Domain V of hCyPB has 10 amino acids not found in the CyPA family of proteins. Domain V of yCyPB has only 5 amino acids with no obvious homology to domain V in hCyPB. hCyPB and rCyLP are identical in domain V, but rCyLP apparently continues for an additional 23 amino acids represented by domain VI (Fig. 2) . Expression of hCyPB in E. coli: Purification and Characterization. Following the general strategy for the purification of hCyPA (11), hCyPB was expressed and purified from E. coli. As shown in Fig. 3 , recombinant hCyPB expressed in E. coli yields a protein of about 21 kDa, approximately 3-4 kDa larger than hCyPA. The N-terminal sequence analysis of the E. coli-expressed hCyPB protein (DEKKKGPKVTVKVYF, which corresponds to residues 26-40 in hCyPB) (Fig. 1 Upper) indicated that the first 25 residues had been removed in E. coli. It has not been assessed whether hCyPB is secreted into the E. coli periplasm as is the E. coli CyP (25) .
Pure hCyPB is an active PPIase as determined in the standard tetrapeptide chromogenic PPIase assay. As depicted in Table 1 , hCyPB 'shows a kcat/Km of 6.3 x 106 M-1s.1. When recombinant hCyPA was assayed in parallel, its catalytic efficiency was found to be 2.5-fold less than that of hCyPB. The hCyPB PPIase activity at an enzyme concentration of 6.9 nM was found to be inhibited by CsA sensitive to CsA. A distinguishing feature of hCyPB is the presence of an N-terminal signal sequence that is removed upon expression in E. coli. This signal sequence has characteristics common to those found in ER-directed proteins, which suggests that hCyPB will be found within the ER or in distal compartments along the secretory pathway (21, 22) .
The existence of a second CyP in humans is paralleled in the yeast Saccharomyces cerevisiae, for which two proteins with CyP homology have been reported. The first, yCyPA (26) , is homologous to hCyPA (27) . The second, yCyPB (10) sequence of hCyPB would dictate that it functions in the ER or more distal portions of the secretory pathway. Because hCyPB lacks a Lys-Asp-Glu-Leu ER-retention signal found in most ER-resident proteins (32) (33) (34) (35) , assignment of definitive subcellular localization and secretory potential will require immunocytochemical studies. The possible secretion of hCyPB may have important clinical ramifications for patients undergoing CsA therapy. The data presented here suggest that CyP diversity can arise by additions of N-terminal and C-terminal extensions flanking the central CyP core domain. This central core domain is likely to include both the PPlase catalytic site and the CsA-binding site. While both hCyPA and hCyPB are expressed in T cells and are potential mediators of the immunosuppressive effects of CsA, additional T-cell-specific CyP genes or transcriptional variants ofCyPA and CyPB may play critical roles in T-cell activation.
